Literature DB >> 12198294

Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.

Vivian Cody1, Nikolai Galitsky, Joseph R Luft, Walter Pangborn, Sherry F Queener, Aleem Gangjee.   

Abstract

Structural studies of two ternary complexes of Pneumocystis carinii dihydrofolate reductase (pcDHFR) with the cofactor NADP(+) and potent antifolates, the N9-C10 reversed-bridge inhibitor 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline (1) and its 3',5'-dimethoxypyrido[2,3-d]pyrimidine analog (2), were carried out. Data for the monoclinic crystals were refined to 1.90 A resolution for the complex with (1) (R = 0.178) and to 2.1 A resolution for the complex with (2) (R = 0.193). The effect of the N9-C10 reversed-bridge geometry is to distort the bridge from coplanarity with the pyrido[2,3-d]pyrimidine or quinazoline ring system and to twist the C10 methylene conformation toward a gauche conformation. This change also influences the conformation of the methoxybenzyl ring, moving it away from a trans position. This change places the 5'-methoxy group deeper within the hydrophobic pocket made by Ile65, Pro66 and Phe69 of the pcDHFR active site. These results also revealed the first observation of an unusual conformation for the reversed-bridge geometry (C5-C6-N9-C10 torsion angle) in antifolate (2). The electron density is consistent with the presence of two models (conformers 2-1 and 2-2) that result from inversion of the geometry at N9. The four examples of N9-C10 reversed-bridge antifolates cluster in two conformations, with the structure of quinazoline (1) similar to that previously reported for its 2',5'-dimethoxypyrido[2,3-d]pyrimidine analog (3). The two conformers of (2) differ from these and each other by a twisted-bridge geometry that results in the dimethoxybenzyl ring occupying the same conformational space. Conformer 2-2 also has the N9-C10 reversed bridge perpendicular to the pyrido[2,3-d]pyrimidine plane, in contrast to the gauche-trans conformation normally observed. As a result of these changes, the N9 methyl probes conformational space in the active site not normally occupied by antifolate structures. The N9 methyl of conformer 2-2 makes close contacts to the conserved Leu25 as well as the hydroxyl O atoms of the nicotinamide ribose and Ser64, whereas the other three reversed-bridge conformers make weak hydrophobic contacts with Ile123, Thr61 and Ile65. These antifolates are ten times more selective for pcDHFR than the C9-N10 bridge parent trimetrexate. However, pyrido[2,3-d]pyrimidines (2) and (3) are three times more selective for pcDHFR than quinazoline (1) is for rat liver DHFR. These data suggest that the loss of hydrogen-bonding interactions with N8 is more important to potency than the interactions of the methoxybenzyl substituents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12198294     DOI: 10.1107/S0907444902010442

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  7 in total

1.  Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.

Authors:  Alexis Nzila; Matthias Rottmann; Penchit Chitnumsub; Stevens M Kiara; Sumalee Kamchonwongpaisan; Cherdsak Maneeruttanarungroj; Supannee Taweechai; Bryan K S Yeung; Anne Goh; Suresh B Lakshminarayana; Bin Zou; Josephine Wong; Ngai Ling Ma; Margaret Weaver; Thomas H Keller; Veronique Dartois; Sergio Wittlin; Reto Brun; Yongyuth Yuthavong; Thierry T Diagana
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

2.  Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Sudhir Raghavan; Sherry F Queener; Roy L Kisliuk; Vivian Cody
Journal:  J Med Chem       Date:  2013-05-21       Impact factor: 7.446

3.  Novel non-classical C9-methyl-5-substituted-2,4-diaminopyrrolo[2,3-d]pyrimidines as potential inhibitors of dihydrofolate reductase and as anti-opportunistic agents.

Authors:  Aleem Gangjee; Jie Yang; Sherry F Queener
Journal:  Bioorg Med Chem       Date:  2006-09-28       Impact factor: 3.641

4.  Elucidating features that drive the design of selective antifolates using crystal structures of human dihydrofolate reductase.

Authors:  Kristen M Lamb; Narendran G-Dayanandan; Dennis L Wright; Amy C Anderson
Journal:  Biochemistry       Date:  2013-10-03       Impact factor: 3.162

5.  CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase.

Authors:  Osvaldo A Santos-Filho; Delphine Forge; Lucas V B Hoelz; Guilherme B L de Freitas; Thiago O Marinho; Jocley Q Araújo; Magaly G Albuquerque; Ricardo B de Alencastro; Nubia Boechat
Journal:  J Mol Model       Date:  2012-04-14       Impact factor: 1.810

6.  Interpretable correlation descriptors for quantitative structure-activity relationships.

Authors:  Benson M Spowage; Craig L Bruce; Jonathan D Hirst
Journal:  J Cheminform       Date:  2009-12-24       Impact factor: 5.514

7.  N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.

Authors:  Aleem Gangjee; Ona O Adair; Michelle Pagley; Sherry F Queener
Journal:  J Med Chem       Date:  2008-09-05       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.